PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Monica Tang*, Rachel L. O'Connell, Frederic Amant, Philip Beale, Orla McNally, Katrin M. Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin, Tania Moujaber, Catherine J. Kennedy, Anna deFazio, King Tan, Yoland Antill, Jeffrey Goh, Tony Bonaventura, James Scurry, Michael Friedlander

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    68 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors'. Together they form a unique fingerprint.

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science